N
Neal Oden
Researcher at University of Wisconsin-Madison
Publications - 76
Citations - 2608
Neal Oden is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Central retinal vein occlusion & Randomized controlled trial. The author has an hindex of 22, co-authored 76 publications receiving 1903 citations.
Papers
More filters
Journal ArticleDOI
A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5
Michael S. Ip,Ingrid U. Scott,Paul C. VanVeldhuisen,Neal Oden,Barbara A Blodi,Marian R. Fisher,Lawrence J. Singerman,Michael J. Tolentino,Clement K. Chan,Victor H. Gonzalez +9 more
TL;DR: Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial.
Journal ArticleDOI
Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial
Lisa R. Metsch,Daniel J. Feaster,Lauren Gooden,Tim Matheson,Maxine L. Stitzer,Moupali Das,Moupali Das,Mamta K. Jain,Mamta K. Jain,Allan Rodriguez,Wendy S. Armstrong,Gregory M. Lucas,Ank E. Nijhawan,Mari-Lynn Drainoni,Patricia Herrera,Pamela Vergara-Rodriguez,Jeffrey M. Jacobson,Michael J. Mugavero,Meg Sullivan,Eric S. Daar,Deborah McMahon,David C. Ferris,David C. Ferris,Robert Lindblad,Paul C. VanVeldhuisen,Neal Oden,Pedro C. Castellon,Susan Tross,Susan Tross,Louise Haynes,Antoine Douaihy,James L. Sorensen,David S. Metzger,Raul N. Mandler,Grant Colfax,Carlos del Rio +35 more
TL;DR: Among hospitalized patients with HIV infection and substance use, patient navigation with or without financial incentives did not have a beneficial effect on HIV viral suppression relative to nonsuppression or death at 12 months vs treatment as usual, and findings do not support these interventions in this setting.
Journal ArticleDOI
Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
Ingrid U. Scott,Paul C. VanVeldhuisen,Michael S Ip,Barbara A Blodi,Neal Oden,Carl C Awh,Derek Y Kunimoto,Dennis M. Marcus,John J Wroblewski,Jacqueline King +9 more
TL;DR: Among patients with macular edema due to central retinal or hemiretinal vein occlusion, intravitreal bevacizumab was noninferior to aflibercept with respect to visual acuity after 6 months of treatment.
Journal ArticleDOI
SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion.
Ingrid U. Scott,Paul C. VanVeldhuisen,Neal Oden,Michael S. Ip,Barbara A Blodi,J. Michael Jumper,Maria Figueroa +6 more
TL;DR: OCT-measured center point thickness represents a useful tool for the detection and monitoring of macular edema in retinal vein occlusion, but it cannot reliably substitute for visual acuity measurements.
Journal ArticleDOI
Brief intervention for patients with problematic drug use presenting in emergency departments: a randomized clinical trial.
Michael P. Bogenschutz,Dennis M. Donovan,Raul N. Mandler,Harold I. Perl,Alyssa A. Forcehimes,Cameron Crandall,Robert Lindblad,Neal Oden,Gaurav Sharma,Lisa R. Metsch,Michael S. Lyons,Ryan P. McCormack,Wendy Macias-Konstantopoulos,Antoine Douaihy +13 more
TL;DR: In this paper, the authors compared the effects of a brief intervention with telephone boosters (BI-B) with those of screening, assessment, and referral to treatment (SAR) and minimal screening only (MSO) among drug-using ED patients.